Third‐Generation Nanopore Sequencing for Post‐Transplant Chimerism Monitoring
HLA · 2026
DOI: 10.1111/tan.70770 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2026. Verfasst von Pascal Pedini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Immunogenetics Laboratory, Reference Laboratory for the Study of Chimerism, Établissement Français du Sang PACA-Corse, Marseille, France. Hauptthemen laut MEDLINE: Transplantation Chimera, Hematopoietic Stem Cell Transplantation, Nanopore Sequencing, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Post‐transplant chimerism monitoring is a cornerstone of hematopoietic stem cell transplantation (HSCT) follow‐up, providing early and clinically actionable information on engraftment, graft rejection and disease relapse. Analytical strategies have progressively evolved from STR‐based assays towards more sensitive molecular approaches, including qPCR, dPCR and next‐generation sequencing (NGS). Although NGS offers high analytical robustness and multiplexing capacity, its routine use remains limited by turnaround time and batch‐dependent workflows, restricting its applicability in urgent clinical contexts. Third‐generation sequencing (TGS), based on real‐time DNA sequencing, emerges as a complementary approach combining molecular sensitivity with enhanced operational flexibility. We evaluated ONtrack (Eurobio/GenDx), the first commercial TGS‐based assay for post‐transplant chimerism quantification using Oxford Nanopore Technologies, currently available through an early access program. Thirty samples were analysed, including external quality assessment materials, manufacturer controls and clinical specimens from three transplanted patients. Sample types included whole blood, bone marrow and CD3 + ‐sorted cell fractions. ONtrack results were compared with routinely used methods (qPCR, dPCR and NGS). ONtrack demonstrated excellent analytical performance, with strong correlations to qPCR ( R 2 = 0.955), dPCR ( R 2 = 0.990) and NGS ( R 2 = 0.998). Mixed chimerism was reliably detected down to 0.5%, and Bland–Altman analyses confirmed good agreement across methods. Z‐score analysis showed satisfactory performance for all evaluated samples. Notably, the complete analytical workflow could be completed in approximately 3 h for a single sample, with fully automated data processing and integrated quality controls. Beyond analytical accuracy, ONtrack offers high operational versatility, enabling both urgent single‐sample testing and batch analyses using a standardised workflow. Although the limited number of markers may restrict detection of ultra‐low microchimerism, TGS represents a valuable complementary solution for early post‐transplant monitoring, particularly in decentralised laboratory settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunogenetics Laboratory, Reference Laboratory for the Study of Chimerism, Établissement Français du Sang PACA-Corse, Marseille, France.
- Aix Marseille University, CNRS, EFS, ADES, Marseille, France.
- Department of Pediatric Hematology, Immunology, and Oncology, APHM, Timone Children's Hospital, Marseille, France.
ORCID-Profile: Pascal Pedini
Zitieren
APA
Pedini, P., Rateau, E., Maioli, S., Cherouat, N., Basire, A., Barlogis, V., Picard, C., & Frassati, C. (2026). Third‐Generation Nanopore Sequencing for Post‐Transplant Chimerism Monitoring. HLA. https://doi.org/10.1111/tan.70770
Vancouver
Pedini P, Rateau E, Maioli S, Cherouat N, Basire A, Barlogis V, et al. Third‐Generation Nanopore Sequencing for Post‐Transplant Chimerism Monitoring. HLA. 2026. doi:10.1111/tan.70770
BibTeX
@article{Pedini2026,
author = {Pedini, Pascal and Rateau, Emma and Maioli, Sandrine and Cherouat, Nicem and Basire, Agnès and Barlogis, Vincent and Picard, Christophe and Frassati, Coralie},
title = {Third‐Generation Nanopore Sequencing for Post‐Transplant Chimerism Monitoring},
journal = {HLA},
year = {2026},
doi = {10.1111/tan.70770}
}
EUVIMED